Literature DB >> 26687885

Frequency and outcomes of severe hyperlactatemia after elective cardiac surgery.

J Ross Renew1, David W Barbara1, Joseph A Hyder1, Joseph A Dearani2, Mariela Rivera3, Juan N Pulido4.   

Abstract

BACKGROUND: Hyperlactatemia is relatively common in the cardiac surgical patient and is usually considered a marker of illness severity. The frequency and impact of severe hyperlactatemia after elective cardiac surgery has not been described, and prognosis may be different compared with that for other surgical or medical critically ill patient populations.
METHODS: We conducted a retrospective study to evaluate the hospital course and outcomes of patients who developed severe postoperative hyperlactatemia (SPHL; lactate >10 mmol/L) after elective cardiac surgery, from January 1, 2008 to December 31, 2012, at a large, academic, tertiary referral center.
RESULTS: Of 9580 cardiac surgical patients who met inclusion criteria, 121 (1.26%) developed SPHL. The most common cause was cardiogenic shock (53.8%). In-hospital mortality was 40.5% but varied widely based on the cause of the SPHL. All patients with definite mesenteric ischemia (n = 5) or extremity compartment syndrome (n = 6) at the time of SPHL died in the hospital. Forty patients (33.1%) were discharged to home, whereas 32 (26.4%) were discharge to a skilled-care facility.
CONCLUSIONS: Severe postoperative hyperlactatemia is rare after elective cardiac surgery. Although this phenomenon continues to be associated with mortality, >50% of patients survived to hospital discharge, a more favorable prognosis, compared with other patient populations based on lactate levels alone. Important exceptions were patients who had extremity compartment syndrome or mesenteric ischemia, which were associated with in-hospital death in all cases. In all other etiologic groups, a substantial proportion of patients were discharged to home.
Copyright © 2016 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiac surgery; hyperlactatemia; lactic acidosis; perioperative care; shock

Mesh:

Year:  2015        PMID: 26687885     DOI: 10.1016/j.jtcvs.2015.10.063

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  6 in total

1.  Serum lactate level as a useful predictor of clinical outcome after surgery: an unfulfilled potential?

Authors:  Lorenzo Cobianchi; Andrea Peloso; Claudia Filisetti; Francesco Mojoli; Fabio Sciutti
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  Postoperative Serum Lactate Levels for In-Hospital Mortality Prediction Among Heart Transplant Recipients.

Authors:  Anna Kędziora; Karol Wierzbicki; Jacek Piątek; Hubert Hymczak; Izabela Górkiewicz-Kot; Irena Milaniak; Paulina Tomsia; Dorota Sobczyk; Rafał Drwiła; Bogusław Kapelak
Journal:  Ann Transplant       Date:  2020-05-26       Impact factor: 1.530

3.  Does severe hyperlactatemia during cardiopulmonary bypass predict a worse outcome?

Authors:  Aniss Seghrouchni; Noureddine Atmani; Younes Moutakiallah; Abdelkader Belmekki; Youssef El Bekkali; Mahdi Ait Houssa
Journal:  Ann Med Surg (Lond)       Date:  2021-12-21

4.  Early dynamic behavior of lactate in predicting continuous renal replacement therapy after surgery for acute type A aortic dissection.

Authors:  Zhigang Wang; Jingfang Xu; Yubei Kang; Ling Liu; Lifang Zhang; Dongjin Wang
Journal:  Front Cardiovasc Med       Date:  2022-07-26

5.  Outcomes of hyperlactatemia on admission in critically ill patients with acute myocardial infarction: A retrospective study from MIMIC-IV.

Authors:  Ting Lu; Liao Tan; Kai Xu; Jia Liu; Chong Liu; Guogang Zhang; Ruizheng Shi; Zheng Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-23       Impact factor: 6.055

6.  Base excess is superior to lactate-levels in prediction of ICU mortality after cardiac surgery.

Authors:  Bjoern Zante; Hermann Reichenspurner; Mathias Kubik; Stefan Kluge; Joerg C Schefold; Carmen A Pfortmueller
Journal:  PLoS One       Date:  2018-10-05       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.